MedPath
HSA Approval

NORPHEN TABLET

SIN12142P

NORPHEN TABLET

NORPHEN TABLET

December 5, 2002

ATLANTIC PHARMACEUTICAL (S) PTE LTD

ATLANTIC PHARMACEUTICAL (S) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantATLANTIC PHARMACEUTICAL (S) PTE LTD
Licence HolderATLANTIC PHARMACEUTICAL (S) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

M03BC51

orphenadrine, combinations

Manufacturer Information

atlantic pharmaceutical (s) pte ltd

ATLANTIC LABORATORIES CORPN LTD

Active Ingredients

ORPHENADRINE CITRATE

35 mg

Orphenadrine

PARACETAMOL

450 mg

Acetaminophen

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

NORPHEN TABLET - HSA Approval | MedPath